ClinicalTrials.gg

Program

TVAX-008

A development code.

Its studies are mostly in Hepatitis B, Chronic, led by 3 companies.

Furthest: phase 2, since Sep 11, 20255 company-led studies, 5 open or runningNext primary completion: Sep 22, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grand Theravac Life Sciences (Nanjing)33 open or runningphase 2since Sep 11, 2025Sep 11, 2025none ahead
Ausper Biopharma11 open or runningphase 2since Oct 9, 2026Oct 9, 2026Sep 22, 2028phase 2 · NCT07876856
Grand Theravac Life Sciences (Hangzhou)11 open or runningphase 2since Oct 13, 2026Oct 13, 2026Sep 22, 2028phase 2 · NCT07897448

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 11, 2025First studies: 2 phase 2 studiesNew to Grand Theravac Life Sciences (Nanjing)Grand Theravac Life Sciences (Nanjing) · NCT07179653, NCT07190742
  2. Sep 24, 2025Early phase 1 study in Hepatitis B, ChronicGrand Theravac Life Sciences (Nanjing) · NCT07204236 · 20 enrolled · China
  3. Oct 9, 2026Ausper Biopharma's first study: phase 2 study in Hepatitis B, ChronicNew to Ausper BiopharmaAusper Biopharma · NCT07876856 · 105 planned
  4. Oct 13, 2026Grand Theravac Life Sciences (Hangzhou)'s first study: phase 2 study in Hepatitis B, ChronicNew to Grand Theravac Life Sciences (Hangzhou)Grand Theravac Life Sciences (Hangzhou) · NCT07897448 · 105 planned

Ahead

  1. Sep 22, 2028Primary completion: phase 2 study in Hepatitis B, ChronicGrand Theravac Life Sciences (Hangzhou) · NCT07897448
  2. Sep 22, 2028Primary completion: phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07876856

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07897448Hepatitis B, Chronic2Not yet recruitingGrand Theravac Life Sciences (Hangzhou)Sep 22, 2028105
NCT07876856Hepatitis B, Chronic2Not yet recruitingAusper BiopharmaSep 22, 2028105
NCT07204236Hepatitis B, Chronic · ChinaEarly 1Active, not recruitingGrand Theravac Life Sciences (Nanjing)Mar 1, 202520
NCT07190742Hepatitis B, Chronic · China2Active, not recruitingGrand Theravac Life Sciences (Nanjing)Oct 17, 202480
NCT07179653HBV Infection · China2Active, not recruitingGrand Theravac Life Sciences (Nanjing)Dec 202548

How it is read

Names in the registry

  • “TVAX-008”, 5 entries

Codes read as this program: TVAX008.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.